Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
Clearmind Medicine (NASDAQ: CMND) has announced the publication of a European patent (EP 4531826) for its psychedelic-based combination therapy targeting cocaine addiction. The therapy combines MEAI (5-methoxy-2-aminoindane) with N-Acylethanolamines, including Palmitoylethanolamide (PEA).
Preclinical trials conducted at Bar-Ilan University demonstrated that MEAI significantly reduced cocaine-seeking behavior in animals without affecting their response to natural rewards like sucrose. This suggests the treatment specifically targets drug-related compulsions rather than the general reward system.
The patent publication strengthens Clearmind's intellectual property portfolio and complements similar filings in other markets. The development is part of an ongoing collaboration with SciSparc Ltd. (NASDAQ: SPRC) to explore combined MEAI and PEA-based technologies for treating central nervous system disorders.
Clearmind Medicine (NASDAQ: CMND) ha annunciato la pubblicazione di un brevetto europeo (EP 4531826) relativo alla sua terapia combinata a base di sostanze psichedeliche per il trattamento della dipendenza da cocaina. La terapia unisce MEAI (5-metossi-2-aminoindano) con N-Aciletanolamine, tra cui la Palmitoiletanolamide (PEA).
Studi preclinici condotti presso l'Università Bar-Ilan hanno dimostrato che MEAI riduce significativamente il comportamento di ricerca della cocaina negli animali senza influenzare la risposta a ricompense naturali come il saccarosio. Ciò suggerisce che il trattamento agisce specificamente sulle compulsioni legate alla droga, senza alterare il sistema di ricompensa generale.
La pubblicazione del brevetto rafforza il portafoglio di proprietà intellettuale di Clearmind e integra simili domande in altri mercati. Questo sviluppo fa parte di una collaborazione in corso con SciSparc Ltd. (NASDAQ: SPRC) per esplorare tecnologie combinate basate su MEAI e PEA per il trattamento di disturbi del sistema nervoso centrale.
Clearmind Medicine (NASDAQ: CMND) ha anunciado la publicación de una patente europea (EP 4531826) para su terapia combinada basada en psicodélicos dirigida a la adicción a la cocaína. La terapia combina MEAI (5-metoxi-2-aminoindano) con N-Aciletanolaminas, incluyendo Palmitoiletanolamida (PEA).
Ensayos preclínicos realizados en la Universidad Bar-Ilan demostraron que MEAI reduce significativamente el comportamiento de búsqueda de cocaína en animales sin afectar su respuesta a recompensas naturales como la sacarosa. Esto sugiere que el tratamiento apunta específicamente a las compulsiones relacionadas con la droga y no al sistema general de recompensa.
La publicación de la patente fortalece la cartera de propiedad intelectual de Clearmind y complementa solicitudes similares en otros mercados. Este desarrollo forma parte de una colaboración continua con SciSparc Ltd. (NASDAQ: SPRC) para explorar tecnologías combinadas basadas en MEAI y PEA para tratar trastornos del sistema nervioso central.
Clearmind Medicine (NASDAQ: CMND)는 코카인 중독을 대상으로 한 사이키델릭 기반 복합 치료법에 대한 유럽 특허(EP 4531826) 출원을 발표했습니다. 이 치료법은 MEAI (5-메톡시-2-아미노인단)과 팔미토일에탄올아마이드(PEA)를 포함한 N-아실에탄올아민을 결합합니다.
바르일란 대학교에서 수행된 전임상 시험에서 MEAI가 동물의 코카인 탐색 행동을 유의미하게 감소시켰으며 천연 보상제인 자당에 대한 반응에는 영향을 미치지 않는 것으로 나타났습니다. 이는 치료가 일반적인 보상 시스템이 아닌 약물 관련 강박 행동을 구체적으로 겨냥함을 시사합니다.
이번 특허 출원은 Clearmind의 지적 재산권 포트폴리오를 강화하며, 다른 시장에서의 유사 출원과도 보완적입니다. 이 개발은 중추신경계 질환 치료를 위한 MEAI 및 PEA 기반 복합 기술을 탐구하기 위해 SciSparc Ltd. (NASDAQ: SPRC)와 진행 중인 협력의 일환입니다.
Clearmind Medicine (NASDAQ : CMND) a annoncé la publication d’un brevet européen (EP 4531826) pour sa thérapie combinée à base de psychédéliques visant la dépendance à la cocaïne. Cette thérapie associe MEAI (5-méthoxy-2-aminoindane) à des N-Acylethanolamines, dont la Palmitoyléthanolamide (PEA).
Des essais précliniques réalisés à l’Université Bar-Ilan ont montré que le MEAI réduisait significativement le comportement de recherche de cocaïne chez les animaux sans affecter leur réponse aux récompenses naturelles comme le saccharose. Cela suggère que le traitement cible spécifiquement les compulsions liées à la drogue plutôt que le système de récompense général.
La publication du brevet renforce le portefeuille de propriété intellectuelle de Clearmind et complète des dépôts similaires sur d’autres marchés. Ce développement s’inscrit dans le cadre d’une collaboration en cours avec SciSparc Ltd. (NASDAQ : SPRC) pour explorer des technologies combinées à base de MEAI et de PEA pour le traitement des troubles du système nerveux central.
Clearmind Medicine (NASDAQ: CMND) hat die Veröffentlichung eines europäischen Patents (EP 4531826) für seine psychedelisch basierte Kombinationstherapie gegen Kokainabhängigkeit bekannt gegeben. Die Therapie kombiniert MEAI (5-Methoxy-2-Aminoindan) mit N-Acylethanolaminen, darunter Palmitoylethanolamid (PEA).
Präklinische Studien an der Bar-Ilan-Universität zeigten, dass MEAI das kokainbezogene Suchverhalten bei Tieren signifikant reduzierte, ohne deren Reaktion auf natürliche Belohnungen wie Saccharose zu beeinflussen. Dies deutet darauf hin, dass die Behandlung gezielt suchtbezogene Zwänge anspricht und nicht das allgemeine Belohnungssystem.
Die Patentveröffentlichung stärkt das geistige Eigentumsportfolio von Clearmind und ergänzt ähnliche Anmeldungen in anderen Märkten. Die Entwicklung ist Teil einer laufenden Zusammenarbeit mit SciSparc Ltd. (NASDAQ: SPRC), um kombinierte MEAI- und PEA-basierte Technologien zur Behandlung von Erkrankungen des zentralen Nervensystems zu erforschen.
- European patent publication strengthens global IP protection for the company's cocaine addiction treatment
- Preclinical trials showed significant reduction in cocaine-induced cravings
- Treatment specifically targets drug-related compulsions without affecting natural reward responses
- Strategic collaboration with SciSparc Ltd. expands potential applications to various CNS disorders
- Treatment is still in preclinical stage, requiring extensive further testing
- No human trial data available yet
Insights
Clearmind's European patent publication strengthens IP protection for its psychedelic addiction therapy, critical for future commercialization potential.
This European patent publication represents a strategic IP milestone for Clearmind Medicine, expanding their global patent portfolio for their novel psychedelic-based addiction treatment. The patent specifically covers the combination of MEAI (5-methoxy-2-aminoindane) with N-Acylethanolamines like Palmitoylethanolamide (PEA) for treating cocaine addiction.
The territorial expansion to Europe is particularly significant as it complements existing filings in other markets, creating a more comprehensive global IP shield. For biotech companies, especially those working with novel compounds, robust patent protection across major markets is essential for preventing competitors from developing similar treatments and preserving future revenue opportunities.
What makes this patent scientifically intriguing is that it's based on preclinical evidence showing MEAI reduced cocaine-seeking behavior without affecting responses to natural rewards. This selectivity suggests a mechanism that specifically targets drug cravings rather than broadly affecting reward pathways - a critical distinction for addiction treatments where preserving normal reward functions is desirable.
The ongoing collaboration with SciSparc Ltd. to explore combined applications of MEAI and PEA-based technologies indicates a strategy to develop a versatile treatment platform beyond just cocaine addiction, potentially addressing multiple CNS disorders.
While this patent publication doesn't guarantee approval or commercial success, it's a foundational element for Clearmind's business strategy, creating potential barriers to entry for competitors and enhancing the company's attractiveness for partnerships or acquisition. At this preclinical stage, the patent publication represents important progress in de-risking their intellectual property position, though significant clinical development work still lies ahead.
Patent publication in Europe strengthens Clearmind’s global IP position and advances strategic focus on addiction treatment
Vancouver, Canada, May 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today the official publication of a European patent application by the European Patent Office (EPO).
This patent, numbered EP 4531826, covers Clearmind’s proprietary psychedelic-based combination therapy, which includes MEAI (5-methoxy-2-aminoindane) and certain N-Acylethanolamines, such as Palmitoylethanolamide (PEA), for the treatment of cocaine addiction. The application further strengthens Clearmind’s expanding global intellectual property portfolio and complements similar patent filings in other key markets.
The patent is based on preclinical trial results led by Professor Gal Yadid and his team at the Gonda Multidisciplinary Brain Research Center at Bar-Ilan University in Israel. These studies build upon earlier experiments in which animals treated with MEAI exhibited a significant reduction in cocaine-induced cravings.
Further research was conducted in rats to assess whether MEAI’s effects on drug-seeking behavior extended to natural rewards, given that reward-based reinforcement is a fundamental survival mechanism across species. The study produced positive results, demonstrating that while MEAI reduced cocaine-seeking behavior, it did not impair the rats’ response to natural rewards such as sucrose. This finding suggests that MEAI’s impact on drug cravings is not tied to the general reward system, but is specifically targeted at drug-related compulsions.
“This European patent publication marks an important milestone in Clearmind’s strategy to safeguard the intellectual property behind out innovative addiction treatments,” said Adi Zuloff-Shani, CEO of Clearmind. “As part of our broader mission to develop effective, non-addictive therapies for substance use disorders, strengthening our IP across global jurisdictions is key to ensuring long-term commercial and scientific leadership.”
The patent application is part of Clearmind’s ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC), with the aim to explore the combined potential of MEAI and SciSparc’s PEA-based technologies for treating various central nervous system disorders.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses mission to develop effective, non-addictive therapies for substance use disorders and its long-term commercial and scientific leadership. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What is the new European patent for CMND's cocaine addiction treatment?
What were the results of Clearmind Medicine's preclinical trials for cocaine addiction?
Who is Clearmind Medicine (CMND) collaborating with for this treatment?
What stage of development is CMND's cocaine addiction treatment in?
How does Clearmind's MEAI treatment affect the reward system?
